I1877
Isocitric Dehydrogenase (NADP) from porcine heart
Type I, 0.5-3.0 unit/mg solid (plus numerous enzyme activities associated with porcine heart)
Synonym(s):
threo-Ds-Isocitrate: NADP+ oxidoreductase, ICDH, IDH
biological source
Porcine heart
Quality Level
type
Type I
form
solid
specific activity
0.5-3.0 unit/mg solid (plus numerous enzyme activities associated with porcine heart)
storage temp.
−20°C
Looking for similar products? Visit Product Comparison Guide
Biochem/physiol Actions
Isocitrate dehydrogenase (IDH) plays a major role in the Krebs cycle by catalyzing the oxidative decarboxylation of isocitrate. The oxidative decarboxylation of isocitrate generates α-ketoglutarate and NADPH. NADPH produced is essential for the production of fatty acids and cholesterol. This NADP-dependent molecules serves as homodimers.
Analysis Note
Crude
Other Notes
One unit will convert 1.0 μmole of isocitrate to α-ketoglutarate per min at pH 7.4 at 37°C.
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Resp. Sens. 1
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Regulatory Information
低风险生物材料
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
The Molecular Pathogenesis of Glioblastoma
Glioblastoma, 21-31 (2016)
Molecular Testing for Glioblastoma
Diagnostic Molecular Pathology, 339-347 (2017)
Chapter One - Mechanisms of Epigenetic Regulation of Leukemia Onset and Progression
Ntziachristos P, et al.
Advances in Immunology, 117, 1-38 (2013)
Omar Abdel-Wahab et al.
Hematology. American Society of Hematology. Education Program, 2012, 56-64 (2012-12-13)
The myelodysplastic syndromes (MDS) are a clinically and cytogenetically heterogeneous group of clonal diseases characterized by ineffective hematopoiesis, peripheral blood cytopenias, and an increased risk of progression to acute myeloid leukemia. The precise molecular mechanisms behind the development of MDS
Maria Paola Martelli et al.
Blood reviews, 27(1), 13-22 (2012-12-25)
Acute myeloid leukemia (AML) is a molecularly heterogeneous disease. Based on cytogenetics and FISH, AML patients are stratified into three major risk categories: favourable, intermediate and unfavourable. However, prognostic stratification and treatment decision for the intermediate risk category, that mostly
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service